The pharmacokinetics of two etoposide (E) formulations were evaluated in patients with refractory hematologic malignancies receiving high-dose conditioning with autologous stem cell transplantation. Patients were randomized to either E at 800 mg/m 2 (containing polysorbate 80 and polyethylene glycol) or etoposide phosphate (EP) at 910 mg/m 2 on days À7 and À5, prior to melphalan, 80 mg/m 2 on day À5. On day À3, EP was repeated. Plasma E was analyzed after each formulation on days À7 and À5 to compare intrapatient pharmacokinetics. In total, 10 patients were treated: four each with multiple myeloma or Hodgkin's disease and two with nonHodgkin's lymphoma. Mucositis was the major toxicity with seven patients. EP first produced grade 3 mucositis. There was no procedure-related mortality and eight patients remained alive 1 year post-transplant. Cumulative etoposide exposure (AUC) was slightly greater with EP (P ¼ 0.056). Conversely, the volume of distribution was slightly, 33%, larger (P ¼ 0.052) and clearance was increased with the E infusion (P ¼ 0.14). As none of the differences reached statistical significance, both E formulations appear to be pharmacokinetically equivalent in the high-dose transplant setting. The combination of high-dose EP with melphalan is an active preparative regimen prior to ABMT for hematologic malignancies.
malignancies
Treatment with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) represents the standard of care for patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) that have failed conventional chemotherapy, and significantly extends the survival of patients with multiple myeloma (MM). [1] [2] [3] [4] [5] [6] [7] A transplant-conditioning regimen combining high-dose etoposide (E) (1.6-2.5 g/m 2 total dose) with melphalan (120-160 mg/m 2 total dose) has demonstrated high remitting potential in patients with NHL or HD, with complete response rates ranging from 75 to 86% 1, 3 and actuarial survivals approaching 83%. 4 Transplant-conditioning regimens for MM have shown that melphalan, delivered either as a single high-dose treatment or combined with total body irradiation, confers response rates of 38-73%, with evidence for a dose-response relation. 6, 8 Combinations of melphalan with other alkylators, such as cyclophosphamide or busulfan, provide no convincing evidence for improved efficacy, but an increased risk of hepatic and other nonhematologic organ toxicity. 6 E has established activity in myeloma and refractory lymphoid malignancies 9 and displays synergistic cytotoxicity when combined with melphalan in preclinical models. 10, 11 The combination of high-dose melphalan with high-dose E has significant activity in lymphoid malignancies and is well tolerated with modest and manageable hematologic toxicity. [1] [2] [3] [4] Two formulations of E are commercially available. The original formulation (Vepesid R , Bristol Myers Squibb Oncology, Princeton, NJ, USA) is supplied in a cosolvent mixture containing polyethylene glycol 300 (3250 mg) and polysorbate (Tween) 80, (400 mg) in ethanol (q.s. 5 ml) per 100 mg of E. 13 Common treatment-related complications associated with the cosolvent system formulation of E, include infusion-related hypotension and metabolic acidosis. These side effects are believed to derive from the lipophilic surfactant, polysorbate 80, which is known to induce histamine release and hypotension in dogs 13, 14 and has been reported to alter the pharmacokinetics of anticancer agents such as doxorubicin 15, 16 and methotrexate 17 in experimental animal models. Furthermore, when administered in a concentrated form in the high-dose setting, surfactants in the E formulation can cause cracking of polyvinyl chloride (PVC) plastic infusion system components, 18 unless proper precautions are taken. 19, 20 In order to avoid precipitation, the concentration of E must not exceed 0.4 mg/ml. Hence, intravenous administration of high-dose E mandates administration with large volumes of intravenous fluids (up to 10-15 l), which further complicates clinical care and adds to the potential for treatment-related complications.
An alternative E formulation was developed that contains the water-soluble prodrug, etoposide phosphate (EP) (Etopophos R , Bristol Myers Squibb). 21 In comparative clinical trials with intravenous administration, both E formulations, yield similar pharmacologic and toxicologic profiles. [21] [22] [23] [24] Pharmacokinetic studies suggest that EP at a standard dose yields serum E concentrations equivalent to the original formulation, following either oral 25, 26 or intravenous administration. 22, 27 At the higher dose employed in AHSCT, E reportedly produces linear elimination pharmacokinetics, 28 but with a three-fold larger volume of distribution, when compared to standard-dose E historical controls. 29 This effect is believed to derive from polysorbate-80-induced perturbation of membrane permeability. 29 Other attempts to compare the pharmacokinetics of high-dose EP to historical E controls, suggest wide interpatient variability precluding calculation of the steadystate volume of distribution (VD ss ) and the mean residence time (MRT). 30, 31 Only one study has compared the pharmacokinetics of high-dose E and EP within the same patients. 32 To determine if EP can be safely substituted for E in high-dose transplant-conditioning regimens, we compared the pharmacokinetics of high-dose E and EP within the same patients with lymphoid malignancy, and evaluated the safety and toxicity of high-dose EP or E combined with high-dose melphalan prior to AHSCT.
Methods

Patients
Patients with biopsy-proven, relapsed, refractory, or poor prognosis lymphoid malignancy were eligible for the trial. Eligibility was restricted to patients 18-70 years of age with a minimum life expectancy of 6 months. All patients had adequate pulmonary and renal function, cardiac function (documented by ejection fraction), and no prohibitive comorbid diseases, such as uncontrolled diabetes, arrhythmias, heart failure or active infections. Patients with a history of prior malignancy (other than basal cell or squamous cell skin cancers or in situ cervical cancer) were excluded.
Chemotherapy regimen
The administration of all chemotherapy began on day À7 prior to autologous stem cell infusion via a central venous catheter. Standard IV fluids and anti-emetics (ondansetral and dexamethasone) were given at the initiation of chemotherapy. Table 1 summarizes the chemotherapy schedule in which five patient cohorts were prospectively randomized to receive either E as the initial formulation (Schedule A) or EP (Schedule B), yielding 10 patients evaluable for E and EP pharmacokinetics. This schedule allowed for 48 h between the infusion of each E formulation on days À7 and À5 pretransplant.
Autologous stem cells were infused via standard institutional protocol on day 0. All patients received prophylactic treatment with acyclovir, antifungal and antibacterial antibiotics on day+1, well after all chemotherapy was completed. Filgrastim, G-CSF (Neupogent, Amgen, Thousand Oaks, CA, USA) (5 mg/kg) was also administered by subcutaneous injection daily beginning on day+7 poststem cell infusion. The E and EP doses were equivalent, based on E base content.
Toxicity grading
Toxicities were graded according to the Autologous Blood Cell Transplantation Toxicity Criteria. 33 
Pharmacokinetics
Blood samples (10 ml) for E pharmacokinetic analysis were collected from a peripheral venous access site distant from that used for drug infusion. Seven samples were obtained relative to E and EP infusions, including time 0 (preinfusion), end of infusion (2 h) and at 2, 4, 8, 12 and 24 h after infusion completion. Plasma was immediately separated by centrifugation at 41C and stored at À801C in plastic cryotubes until analyzed by reverse-phase HPLC.
Etoposide analysis by HPLC
The analytical determination of total E (free and protein bound) in plasma was measured by a modification of an HPLC method described by Brooks et al. 27 Free or ultrafilterable (nonprotein bound) E was not measured. An internal standard method of analysis was employed. A standard curve for E was prepared by adding 10, 20, 40, 60, 80 and 100 mg/ml E to 1.0 ml of expired human plasma. A 5.0 mg sample of b-estradiol (Sigma Chemical, St Louis, MO, USA) was added as an internal standard. Each sample was vortexed and spun for 5 min at 5000 rpm in microcentrifuge tubes prior to extraction. The analytes were extracted from plasma using Bond Elut s (Varian, Harbor City, CA, USA) C18 columns. A 300 ml volume of 100% acetonitrile was used to elute the analytes from this preparative column. The eluent was subjected to reverse-phase HPLC under the following conditions. Solution A contained 50% acetonitrile and 50% methanol by volume. Solution B contained 100% water. A gradient from 10% A, 90% B to 50% A, 50% B was changed in a linear fashion over 15 min. An Alltech (Deerfield IL, USA), 5 mm, C18 column (4.6 Â 250 mm) was employed. The flow rate was 1.5 ml/ min. Analytes were detected at 230 nm u.v. absorbance. Injections were 100 ml and each sample was run in duplicate. Solvent delivery, sample injection and analyte detection were all performed on a Hewlett-Packard 1050 series HPLC system (Santa Clarita, CA, USA). Under these conditions, E and b-estradiol eluted at 8.8 and 13.8 min, respectively.
Prior to the analysis of patient sample unknowns, three standard curves were run on 3 consecutive days. The integrated ratio of the area under the curve for E/bestradiol was used to measure concentration and to prepare a standard curve. A typical linear standard curve was defined by slope ¼ 0.103198, y-intercept ¼ À0.18169,
The patient plasma samples were extracted and chromatographed in an identical fashion to the standards. Patient samples were stored at À801C and were thawed immediately prior to analysis. A measure of 5 mg of b-estradiol in 10 ml methanol was added to each unknown. Three daily standards were run for every seven patient samples to ensure the day-to-day reproducibility of the assay.
Acetonitrile and methanol were purchased from Burdick and Jackson, Muskegon, MI, USA. E was provided from Bristol-Myers Squibb, Co, Plainfield, NJ, USA. A C18 column was purchased from Alltech, Deerfield, IL, USA. Microvolumes were measured using Hamilton microsyringes.
Pharmacokinetic analysis
Plasma concentration vs time data of E was analyzed by a noncompartmental model approach using the WINNON-LIN program (version 3.0 Pharsight Corp, Mountain View, CA, USA). Specifically, the terminal log-linear phase of the plasma concentration-time curve was analyzed by leastsquares linear regression. The terminal elimination rate constant, K, was determined as the absolute value of the slope of the regression line. The elimination half-life, t 1/2 , was determined as 0.693/K. The maximum plasma concentration (C max ) and time to reach the maximum concentration (t max ) were determined by visual inspection of the concentration-time profile. The area under the plasma concentration-time curve (AUC) and the area under the first moment curve (AUMC) were calculated by the trapezoidal rule with extrapolation to time infinity. The MRT was determined from the following relation: MRT ¼ (AUMC/AUC)À(T/2), where T is the infusion time. Systemic clearance (CL) was calculated as the quotient of total dose infused divided by AUC. Steadystate volume of distribution was determined from the following equation: V ss ¼ CL Â MRT. The values were reported as mean plus/minus 1 s.d.
Statistical analysis
Prior to statistical analysis, AUC and C max were normalized by the dose administered. C max /dose, AUC/dose, t 1/2 , CL and V ss of E of the two formulations were compared using a paired t-test. Table 2 ). All patients were evaluable for E/EP pharmacokinetics and toxicity.
Results
Patient characteristics
Ten patients were registered between October 1998 and January 2000 and assigned to treatment with E/EP+melh-palan Schedule A (n ¼ 5) or Schedule B (n ¼ 5). Diagnoses included MM (n ¼ 5), HD (n ¼ 3) failing conventional chemotherapy (n ¼ 1) NHL (n ¼ 2). Ages ranged from 28 to 64 years (median, 48) and included seven males and three females (
Engraftment
In all, 9 patients received a CD34+ progenitor cell dose 41.50 Â 10 6 /kg, meeting the institutional threshold for rapid trilineage engraftment; whereas one patient No. 9 with primary refractory NHL received a suboptimal progenitor cell dose of 1.36 Â 10 6 CD34+cells/kg ( Table 2 ). All patients experienced prompt neutrophil recovery, exceeding an absolute neutrophil count of 500/ ml by a median of 11 days post-transplant. By day +100, one died of progressive disease (NHL) and one patient (HD) was lost to follow-up. Of the eight remaining patients, four experienced delayed platelet engraftment (o100 000 at day +100) that was not explained by the CD34 progenitor cell dose infused (all 42 Â 10 6 /kg). Among the latter patients, one had failed a prior AHSCT, whereas the remaining patients were heavily pretreated for MM. As shown in Table 2 , there is no obvious correlation with time to engraftment, for those receiving either E formulation first.
Toxicity
All 10 patients were evaluable for early procedure-related toxicities through day+30 (Table 3) . Seven patients developed grade 2 mucositis, defined as painful ulcerations resulting in complete inanition, inability to maintain enteral intake other than water and requiring narcotic analgesia for less than 2 weeks. Three patients experienced grade 3 mucositis (defined by a duration exceeding 2 weeks). This includes one patient who required intubation for airway preservation. All three patients developing grade 3 mucositis received the Schedule B-conditioning sequence.
One patient developed grade 2 nausea/vomiting during the conditioning regimen (defined as repeated vomiting for less than 2 weeks despite antiemetics) and two patients had grade 3 nausea/vomiting (ie intractable vomiting, unable to retain water despite maximal antiemetic therapy and persisting for more than 2 weeks). Eight of the patients experienced no skin toxicity (grade 0), whereas two patients developed grade 1 skin toxicity (dry desquamation or painful erythema). Hypertension complicated the chemotherapy infusion in one individual with no prior history. One patient developed a grade two atrial tachyarrhythmia. There was no procedure-related mortality through day 100, and eight patients were alive 1 year post-transplant.
Pharmacokinetics of high-dose E and EP
The HPLC assay was shown to have a coefficient of variation of 6.8% for three repetitions of standard curves, whereas the day-to-day variation ranged from 2 to 16% (median 6%). Figure 1 compares the plasma disappearance curves for the two formulations of E. After the termination of the infusion, the plasma concentrations decline gradually as a function of time. Although the variation is large, each mean EP concentration is higher than the corresponding time point with E. Table 4 summarizes the pharmacokinetic parameters of E. Mean E peak plasma levels (C max ) were 142.0 and 209.2 mg/ml following E and EP, respectively. The corresponding mean E area under the plasma conc Â time curve (AUC) values were 1287 hmg/ml for E and 1770 hmg/ml for EP. No statistically significant difference was seen in the C max values (P ¼ 0.16), although a trend approaching significance was observed for a 33% larger AUC with EP (P ¼ 0.056). The mean plasma half-life (t 1/2 ,), CL and volume of distribution at steady state (V ss ) values following E treatment were 11.1 h, 11.6 ml/min/m 2 and 8.40 l/m 2 , respectively. The corresponding mean values following EP were t 1/2 of 9.98 h, CL of 9.84 ml/min/m 2 and V ss of 6.29 l/ m 2 . The fraction converted from EP to E (bioavailability; F) could be estimated using the ratio of the AUC of E after EP administration to that after E administration. This estimation assumes that the clearance of E is the same after E vs EP administration. With this calculation, an average F value of 1.25 was observed. Since the F value cannot be greater than unity, an F value of 1.25 suggests that the clearance assumption may not be valid. The F value therefore was not reported. since the fraction that converted from EP to E is not known, the CL and V ss of E estimated following EP treatment are hybrid terms of CL/F and V ss /F, respectively. If EP is completely converted (F ¼ 1) to E, the hybrid terms are simplified to true CL and V ss values, otherwise (ie, Fo1), the estimated values are greater than the true CL and V ss values. There was no statistically significant difference in t 1/2 (P ¼ 0.42) and the apparent CL values (P ¼ 0.14) between the two formulations, but there was borderline significance for a 1/3 larger V ss values with E (P ¼ 0.052).
Discussion
Several prior studies have characterized the pharmacokinetic profile of high-dose E in the original formulation (E), 28, 34 or as E phosphate (EP). 21, 26, 27, [30] [31] [32] In both settings, the AUC for E increased linearly with dose; however, in most studies, possible pharmacokinetic differences related to the formulation per se could not be assessed because of the limitations of interpatient variability. The current study represents the second report after Reif et al 32 to characterize pharmacokinetic profiles for each E formulation in patients receiving high-dose therapy using an intrapatient, crossover design. One other prior trial compared E and EP pharmacokinetics at standard doses of 150 mg/m 2 . 23 Unfortunately, a third prior pharmacokinetic study of high-dose EP did not report a mean V d because of large interpatient variances in V d values. 30 A comparative summary of E pharmacokinetics is presented in Table 5 for the three studies that administered both high and standard doses of the two formulations to the same patients. This comparison shows that there is good agreement between the three studies and that the V d and half-life of E and EP do not differ. Since our study administered the highest doses of both formulations, these results significantly extend the linearity of the drug's pharmacokinetics.
The 33% increase in the mean V d seen with E in the current study may be because of the high concentration of pharmacologically active diluents in the E formulation, including the surfactant polysorbate (Tween R ) 80, present at four times the E content, by weight. Furthermore, polyethylene glycol 300 MW is present at 32.5 times the E content by weight. Both excipients are associated with pharmacodynamic effects in vivo. In rodent models, polysorbate 80 has been shown to: (1) increase the volume of distribution of doxorubicin in plasma, 15 (2) to increase the blood barrier penetration of methotrexate 17 and (3) to directly inhibit E elimination from isolated perfused rat livers. 35 Polysorbate 80 also increases the killing by E of lung adenocarcinoma cells, presumably by surfactantenhanced cell membrane penetration. 36 In addition, polyethylene glycol 300 MW, another component in the E formulation, has been shown to increase the free fraction of highly bound drugs such as propanolol in the rat. 37 E is also highly bound to plasma proteins (approximately, 91%). Therefore, a small increase in the unbound fraction, could significantly increase the amount of E available for hepatic clearance and tissue distribution. Indeed, this pattern is observed for E in patients with elevated bilirubin levels, wherein the free fraction can increase from 9 to 27%. 38 We did observe a significant increase in grade 2 or greater regimen-related mucositis in this study compared to our historical experience with E and melphalan. 39 Although all patients in the study received both EP and E, three of the five patients who received EP as initial treatment on day À7 (Schedule A) accounted for all patients with grade 3 mucosal toxicity. However, the reasons for greater mucosal toxicity with the E first regimen remain in question.
Overall, the current findings do not find significant pharmacokinetic differences between E and EP in highdose transplantation therapy of patients with lymphoid malignancies. Although a larger V d was noted after E, the results did not achieve statistical significance and this is consistent with prior studies. The equivalent AUC's for the two formulations further reinforces the conclusion of bioequivalence. Finally, this combination of E (either E or EP), with melphalan, is tolerable and active in the setting of high-dose conditioning prior to autologous stem cell transplantation.
